comparemela.com

Latest Breaking News On - Allergy treatments - Page 1 : comparemela.com

Reckitt Benckiser profits slump on lower sales and Middle East accounting issue

The Durex owner saw its sales volumes plunge following its decision to hike prices by 7.8% over 2023

United kingdomTaylor wimpeyReckitt colmanJames jonesKris lichtReckitt benckiser group onReckitt benckiser groupMiddle eastReckitt benckiserMarkets authorityArticle normalRespiratory allergy treatmentsDetergent cleaning productsHealthcare life sciencesConsumer goodsSpecialized drugs medications

Philips Reaches Agreement With FDA on Ventilator Recall -- 2nd Update

By Elena Vardon Royal Philips reached an agreement with the U.S. Food and Drug Administration on the terms of a settlement linked to recall of its.

Noord hollandUnited statesMarc hesselinkElena vardonPhilips respironicsRoy jakobsDepartment of justiceDrug administrationExecutive roy jakobsRespiratory careNorth americanArticle normalRespiratory allergy treatmentsMedical equipment suppliesHealthcare life sciencesSpecialized drugs medications

Allergy Immunotherapies Market to grow by USD 1 01 billion from 2022 to 2027; Europe to account for 53% of market growth

/PRNewswire/ The allergy immunotherapies market is expected to grow by USD 1.01 billion from 2022 to 2027. In addition, the momentum of the market will.

United statesUnited kingdomJesse maidaPrnewswire theallergyStallergenes greerAllergy therapeuticsAdamis pharmaceuticals corpStallergenes greer ltdTorii pharmaceutical coJubilant pharmova ltdImmunomic therapeutics incCompany profileOptum incDigital health solutionsMerck kgaTechnavio research

GSK to buy asthma drug developer for up to $1 4 billion in pipeline push

The British pharmaceutical giant's deal will give it access to Aiolos' AIO-001 asthma treatment

San franciscoUnited statesUnited kingdomBristol myers squibbAiolos bioLuke mielsBain capital life sciencesJiangsu pharmaceutical coBellus healthAiolo phaseBain capital lifeKaruna therapeuticsWall street journalSunday timesElliott managementChongqing zhifei biological products

How Lowering The Price of a Common Asthma Drug Made it Harder to Get

To avoid Medicaid penalties, Glaxo and other drugmakers lowered prices. For popular asthma drug Flovent HFA, the tactic to replace it with a generic backfired.

Respiratory allergy treatmentsNon life insuranceHealth medical insuranceHealthcare life sciencesSpecialized drugs medicationsFinancial servicesGovernment sponsored health insuranceHealthcare support servicesPharmacy benefit managementNorth americaUnited statesCorporate industrial newsMarkets marketingPolitical general newsRespiratory tract diseasesDemographic health

vimarsana © 2020. All Rights Reserved.